Clinical Trial Update: Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH [Phase 3]

View source ↗

Summary

Phase 3 trial update for burosumab in adults with X-linked hypophosphatemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• Burosumab (burosumab)

Snippet

Sponsor: Kyowa Kirin Pharmaceutical Development Ltd | Conditions: X-linked Hypophosphatemia | Phase 3 | Status: COMPLETED